Cargando…
PPAR-δ agonist affects adipo-chondrogenic differentiation of human mesenchymal stem cells through the expression of PPAR-γ
INTRODUCTION: Peroxisome proliferator–activated receptor (PPAR) subfamily play an important role in chondrogenesis. Previous study has reported that mixture of GW0742 (PPAR-δ agonist), hyaluronic acid (HA) and mesenchymal stem cells (MSCs) enhance chondrogenesis. The purpose of this study is to comp...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society for Regenerative Medicine
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770446/ https://www.ncbi.nlm.nih.gov/pubmed/33426208 http://dx.doi.org/10.1016/j.reth.2020.07.003 |
_version_ | 1783629511012646912 |
---|---|
author | Kim, Dong Hyun Kim, Dong Hwan Heck, Bruce E. Shaffer, Michael Yoo, Keon Hee Hur, Jin |
author_facet | Kim, Dong Hyun Kim, Dong Hwan Heck, Bruce E. Shaffer, Michael Yoo, Keon Hee Hur, Jin |
author_sort | Kim, Dong Hyun |
collection | PubMed |
description | INTRODUCTION: Peroxisome proliferator–activated receptor (PPAR) subfamily play an important role in chondrogenesis. Previous study has reported that mixture of GW0742 (PPAR-δ agonist), hyaluronic acid (HA) and mesenchymal stem cells (MSCs) enhance chondrogenesis. The purpose of this study is to compare with efficacies of commercially available HA and demonstrate correlation of PPAR-γ and PPAR-δ. METHODS: In this experimental study, MSCs were cultured with chondrogenic media and clinical HA gels (Euflexxa®, Synvisc®, Orthovisc® and Supartz®) using micormass culture method. Expression of type Ⅰ, Ⅱ collagen and matrix metalloprotease-13 (MMP-13) was measured by immunoblotting. MSCs were cultured with chondrogenic media and/or HA and/or GW0742 and/or rosiglitazone (PPAR-γ agonist) and/or human osteoarthritis synovial fluid. Immunoblotting was used to measure expression of type Ⅱ collagen and PPAR-γ. To identify the effective dose for chondrogenesis and adipogenesis, either 0.1, 1, 5 or 10 μM of rosiglitazone was added to MSCs in chondrogenic media or adipogenic media. RESULTS: Clinical HA gels inhibited expression of type Ⅰ collagen and enhanced the expression of MMP-13. Type Ⅱ collagen expression was significantly elevated in all treatment groups except Supartz®. GW0742 decreased the expression of PPAR-γ with/without inflammation condition. Rosiglitazone enhanced adipogenesis in a dose-dependent manner and enhanced the expression of type Ⅱ collagen under inflammation condition. Otherwise, the expression of type Ⅱ collagen and formation of chondrocyte spheroids showed a dose-dependent manner with a peak at 1 μM of rosiglitazone. CONCLUSIONS: PPAR-γ has a considerable anti-inflammatory effect and a strong pro-adipogenic effect, which inhibits the chondrogenic effect. PPAR-γ is related with PPAR-δ and shows a chondrogenic effect at lower concentrations. And clinical HA gels shows various efficacy of chondrogenesis. This study suggested that PPAR-γ and PPAR-δ are key regulatory factors of chondrogenesis. |
format | Online Article Text |
id | pubmed-7770446 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Japanese Society for Regenerative Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-77704462021-01-08 PPAR-δ agonist affects adipo-chondrogenic differentiation of human mesenchymal stem cells through the expression of PPAR-γ Kim, Dong Hyun Kim, Dong Hwan Heck, Bruce E. Shaffer, Michael Yoo, Keon Hee Hur, Jin Regen Ther Original Article INTRODUCTION: Peroxisome proliferator–activated receptor (PPAR) subfamily play an important role in chondrogenesis. Previous study has reported that mixture of GW0742 (PPAR-δ agonist), hyaluronic acid (HA) and mesenchymal stem cells (MSCs) enhance chondrogenesis. The purpose of this study is to compare with efficacies of commercially available HA and demonstrate correlation of PPAR-γ and PPAR-δ. METHODS: In this experimental study, MSCs were cultured with chondrogenic media and clinical HA gels (Euflexxa®, Synvisc®, Orthovisc® and Supartz®) using micormass culture method. Expression of type Ⅰ, Ⅱ collagen and matrix metalloprotease-13 (MMP-13) was measured by immunoblotting. MSCs were cultured with chondrogenic media and/or HA and/or GW0742 and/or rosiglitazone (PPAR-γ agonist) and/or human osteoarthritis synovial fluid. Immunoblotting was used to measure expression of type Ⅱ collagen and PPAR-γ. To identify the effective dose for chondrogenesis and adipogenesis, either 0.1, 1, 5 or 10 μM of rosiglitazone was added to MSCs in chondrogenic media or adipogenic media. RESULTS: Clinical HA gels inhibited expression of type Ⅰ collagen and enhanced the expression of MMP-13. Type Ⅱ collagen expression was significantly elevated in all treatment groups except Supartz®. GW0742 decreased the expression of PPAR-γ with/without inflammation condition. Rosiglitazone enhanced adipogenesis in a dose-dependent manner and enhanced the expression of type Ⅱ collagen under inflammation condition. Otherwise, the expression of type Ⅱ collagen and formation of chondrocyte spheroids showed a dose-dependent manner with a peak at 1 μM of rosiglitazone. CONCLUSIONS: PPAR-γ has a considerable anti-inflammatory effect and a strong pro-adipogenic effect, which inhibits the chondrogenic effect. PPAR-γ is related with PPAR-δ and shows a chondrogenic effect at lower concentrations. And clinical HA gels shows various efficacy of chondrogenesis. This study suggested that PPAR-γ and PPAR-δ are key regulatory factors of chondrogenesis. Japanese Society for Regenerative Medicine 2020-07-28 /pmc/articles/PMC7770446/ /pubmed/33426208 http://dx.doi.org/10.1016/j.reth.2020.07.003 Text en © 2020 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Kim, Dong Hyun Kim, Dong Hwan Heck, Bruce E. Shaffer, Michael Yoo, Keon Hee Hur, Jin PPAR-δ agonist affects adipo-chondrogenic differentiation of human mesenchymal stem cells through the expression of PPAR-γ |
title | PPAR-δ agonist affects adipo-chondrogenic differentiation of human mesenchymal stem cells through the expression of PPAR-γ |
title_full | PPAR-δ agonist affects adipo-chondrogenic differentiation of human mesenchymal stem cells through the expression of PPAR-γ |
title_fullStr | PPAR-δ agonist affects adipo-chondrogenic differentiation of human mesenchymal stem cells through the expression of PPAR-γ |
title_full_unstemmed | PPAR-δ agonist affects adipo-chondrogenic differentiation of human mesenchymal stem cells through the expression of PPAR-γ |
title_short | PPAR-δ agonist affects adipo-chondrogenic differentiation of human mesenchymal stem cells through the expression of PPAR-γ |
title_sort | ppar-δ agonist affects adipo-chondrogenic differentiation of human mesenchymal stem cells through the expression of ppar-γ |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770446/ https://www.ncbi.nlm.nih.gov/pubmed/33426208 http://dx.doi.org/10.1016/j.reth.2020.07.003 |
work_keys_str_mv | AT kimdonghyun ppardagonistaffectsadipochondrogenicdifferentiationofhumanmesenchymalstemcellsthroughtheexpressionofpparg AT kimdonghwan ppardagonistaffectsadipochondrogenicdifferentiationofhumanmesenchymalstemcellsthroughtheexpressionofpparg AT heckbrucee ppardagonistaffectsadipochondrogenicdifferentiationofhumanmesenchymalstemcellsthroughtheexpressionofpparg AT shaffermichael ppardagonistaffectsadipochondrogenicdifferentiationofhumanmesenchymalstemcellsthroughtheexpressionofpparg AT yookeonhee ppardagonistaffectsadipochondrogenicdifferentiationofhumanmesenchymalstemcellsthroughtheexpressionofpparg AT hurjin ppardagonistaffectsadipochondrogenicdifferentiationofhumanmesenchymalstemcellsthroughtheexpressionofpparg |